CAM
EGRX

ClariVest Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

ClariVest Asset Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-22,262
Closed -$351K – 963
2023
Q3 		$351K Sell
22,262
-9,030
-29% -$162K 0.02% 364
2023
Q2 		$609K Buy
31,292
+6,988
+29% +$166K 0.03% 323
2023
Q1 		$690K Buy
24,304
+31
+0.1% +$920 0.03% 338
2022
Q4 		$709K Sell
24,273
-216
-0.9% -$6.87K 0.03% 332
2022
Q3 		$646K Sell
24,489
-27
-0.1% -$991 0.03% 324
2022
Q2 		$1.09M Sell
24,516
-6,630
-21% -$305K 0.05% 267
2022
Q1 		$1.54M Buy
31,146
+6,485
+26% +$311K 0.06% 238
2021
Q4 		$1.25M Sell
24,661
-918
-4% -$47.6K 0.04% 290
2021
Q3 		$1.43M Buy
25,579
+14,766
+137% +$727K 0.05% 275
2021
Q2 		$463K Buy
10,813
+25
+0.2% +$1.03K 0.02% 437
2021
Q1 		$450K Sell
10,788
-18,340
-63% -$852K 0.02% 428
2020
Q4 		$1.36M Sell
29,128
-15,869
-35% -$742K 0.05% 239
2020
Q3 		$1.91M Sell
44,997
-1,464
-3% -$64K 0.06% 232
2020
Q2 		$2.23M Buy
46,461
+780
+2% +$38.9K 0.06% 218
2020
Q1 		$2.1M Buy
45,681
+905
+2% +$45.4K 0.06% 192
2019
Q4 		$2.69M Sell
44,776
-19,737
-31% -$1.18M 0.06% 213
2019
Q3 		$3.65M Sell
64,513
-1,000
-2% -$56.2K 0.08% 192
2019
Q2 		$3.65M Buy
65,513
+14,427
+28% +$752K 0.08% 190
2019
Q1 		$2.58M Sell
51,086
-2,720
-5% -$121K 0.05% 286
2018
Q4 		$2.17M Buy
53,806
+13,971
+35% +$720K 0.05% 295
2018
Q3 		$2.76M Sell
39,835
-615
-2% -$46.6K 0.05% 266
2018
Q2 		$3.06M Buy
+40,450
New +$2.54M 0.05% 280
2016
Q2 		– Sell
-16,619
Closed -$673K – 700
2016
Q1 		$673K Buy
16,619
+616
+4% +$39.1K 0.02% 329
2015
Q4 		$1.42M Sell
16,003
-421
-3% -$33.2K 0.04% 232
2015
Q3 		$1.22M Sell
16,424
-4,093
-20% -$341K 0.04% 250
2015
Q2 		$1.66M Buy
20,517
+11,917
+139% +$776K 0.05% 226
2015
Q1 		$360K Sell
8,600
-4,500
-34% -$128K 0.01% 356
2014
Q4 		$204K Buy
13,100
+300
+2% +$3.83K 0.01% 343
2014
Q3 		$162K Buy
+12,800
New +$159K 0.01% 391

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

ClariVest Asset Management's EGRX Position: Q4 2023 in Review

ClariVest Asset Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2023, closing a stake of 22,262 shares — an estimated $351K sold.

ClariVest Asset Management first reported a position in EGRX in Q3 2014 and held it in 29 quarters. The position peaked at $3.65M in Q3 2019. 104 funds tracked by Wall St. Rank hold EGRX as of Q4 2023.

  • ClariVest Asset Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
  • ClariVest Asset Management sold 22,262 Eagle Pharmaceuticals, Inc. shares in Q4 2023, an estimated $351K.
  • ClariVest Asset Management first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2014 and held it in 29 quarters.
  • ClariVest Asset Management's Eagle Pharmaceuticals, Inc. position peaked at $3.65M in Q3 2019.
  • 104 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2023.

Based on ClariVest Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.